CSPIA
ABMD

Cary Street Partners Investment Advisory’s Abiomed Inc ABMD Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30
Closed -$8K – 926
2020
Q3 		$8K Buy
+30
New +$8.64K ﹤0.01% 799

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cary Street Partners Investment Advisory's ABMD Position: Q4 2020 in Review

Cary Street Partners Investment Advisory sold out of Abiomed Inc (ABMD) in Q4 2020, closing a stake of 30 shares — an estimated $8K sold.

Cary Street Partners Investment Advisory first reported a position in ABMD in Q3 2020 and held it in 1 quarter. The position peaked at $8K in Q3 2020. 498 funds tracked by Wall St. Rank hold ABMD as of Q4 2020.

  • Cary Street Partners Investment Advisory reported no remaining Abiomed Inc position as of Q4 2020 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 30 Abiomed Inc shares in Q4 2020, an estimated $8K.
  • Cary Street Partners Investment Advisory first reported a position in Abiomed Inc in Q3 2020 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Abiomed Inc position peaked at $8K in Q3 2020.
  • 498 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2020.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.